Interomex Biopharmaceuticals

Interomex Biopharmaceuticals Inc. is dedicated to the identification of novel biological targets in key cellular processes with the aim of discovering lead compounds for the treatment of disease.

The company’s proprietary Repressed Trans-activator (RTA^TM) technology can be used to detect protein-protein interactions between a host and an infectious agent, as well as within cells in normal and diseased states. A particular advantage of RTA^TM is its ability to detect the interactions of transcription transactivator proteins, which are key control points in viral infections and cell activation.

RTA^TM provides a unique opportunity to create comprehensive protein-protein interaction maps (Interomes^TM) between a host and an infectious agent, or between normal and diseased cells. Since protein-protein interactions are central to all biological processes, especially signal transduction pathways, knowledge of these interactions not only permits a better understanding of the mechanisms of infection, cellular activation and disease, but more importantly, provides new targets for drug discovery using combinatorial approaches.

For careers click here

For further information regarding Interomex please contact:

Gabe Kalmar, Ph.D.
Chief Operating Officer
Interomex Biopharmaceuticals Inc.
1618 Station St.
Vancouver B.C.
Canada

Tel.  604-267-8002
Fax. 604-267-6411